Originally published by our sister publication Gastroenterology & Endoscopy News
By Ted Bosworth
VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of their efficacy end points in their respective placebo-controlled, phase 3 induction trials of ulcerative colitis patients with advanced and largely refractory disease.
In the QUASAR trial, response rates in patients taking guselkumab (Tremfya, Janssen) were still rising for all of the